tradingkey.logo

Astria Therapeutics Inc <ATXS.OQ> expected to post a loss of 55 cents a share - Earnings Preview

ReutersMay 14, 2025 11:03 AM
  • Astria Therapeutics Inc ATXS.OQ ATXS.O is expected to show no change in quarterly revenue when it reports results on August 11 (estimated) for the period ending June 30 2025

  • ​LSEG's mean analyst estimate for Astria Therapeutics Inc is for a loss of 55 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts had fallen by about 6.2% in the last three months. ​

  • Wall Street's median 12-month price target for Astria Therapeutics Inc is $28.00​, above​ its last closing price of $3.90. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Mar. 31 2025

-0.48

-0.48

-0.58

Missed

-21.1

Dec. 31 2025

-0.45

-0.45

-0.20

Beat

55.7

Sep. 30 2024

-0.44

-0.42

-0.42

Met

0.4​

Jun. 30 2024

-0.39

-0.38

-0.43

Missed

-11.7

​​Mar. 31 2024

-0.37

-0.36

-0.38

Missed

-4.4

Dec. 31 2023

-0.78

-0.78

-0.94

Missed

-20.5​

Sep. 30 2023

-0.46

-0.49

-0.63

Missed

-29.6

Jun. 30 2023

-0.49

-0.49

-0.45

Beat

7.6

This summary was machine generated May 14 at 11:03 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles